Cargando…

Development of a prognostic gene signature based on an immunogenomic infiltration analysis of osteosarcoma

Osteosarcoma is the most common primary malignant bone tumour predominantly occurring in children and adolescents with a high tendency of local invasion and early metastases. Currently, tumour immune microenvironment (TME) is becoming the focus of studying of malignant tumours.. However, no sound ev...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Yiyang, Zhang, Hongliang, Ren, Tingting, Huang, Yi, Liang, Xin, Wang, Wei, Niu, Jianfang, Han, Yu, Guo, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7576232/
https://www.ncbi.nlm.nih.gov/pubmed/32820615
http://dx.doi.org/10.1111/jcmm.15687
_version_ 1783597975853858816
author Yu, Yiyang
Zhang, Hongliang
Ren, Tingting
Huang, Yi
Liang, Xin
Wang, Wei
Niu, Jianfang
Han, Yu
Guo, Wei
author_facet Yu, Yiyang
Zhang, Hongliang
Ren, Tingting
Huang, Yi
Liang, Xin
Wang, Wei
Niu, Jianfang
Han, Yu
Guo, Wei
author_sort Yu, Yiyang
collection PubMed
description Osteosarcoma is the most common primary malignant bone tumour predominantly occurring in children and adolescents with a high tendency of local invasion and early metastases. Currently, tumour immune microenvironment (TME) is becoming the focus of studying of malignant tumours.. However, no sound evidence shows a specific immune molecular target in osteosarcoma. We downloaded the gene expression profile and clinical data of osteosarcoma from the TARGET portal, and extracted and normalized via R software. Then, the immune cell infiltration assessed by CIBERSORT and ESTIMATE algorithms. Three survival‐related immune cells and immune score were obtained via Kaplan‐Meier survival analysis, and 232 immune‐related genes were obtained as candidate genes. Enrichment and protein‐protein interaction co‐expression analyses were performed to identify 13 hub genes. Lastly, a seven gene prognostic signature was identified by univariate and multivariate Cox regression analyses. More importantly, our validations and TIMER algorithm suggested this immune‐related prognostic signature a good predictive tool. Our findings have provided novel insights that could demonstrate new targets of immunotherapy in osteosarcoma.
format Online
Article
Text
id pubmed-7576232
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-75762322020-10-23 Development of a prognostic gene signature based on an immunogenomic infiltration analysis of osteosarcoma Yu, Yiyang Zhang, Hongliang Ren, Tingting Huang, Yi Liang, Xin Wang, Wei Niu, Jianfang Han, Yu Guo, Wei J Cell Mol Med Original Articles Osteosarcoma is the most common primary malignant bone tumour predominantly occurring in children and adolescents with a high tendency of local invasion and early metastases. Currently, tumour immune microenvironment (TME) is becoming the focus of studying of malignant tumours.. However, no sound evidence shows a specific immune molecular target in osteosarcoma. We downloaded the gene expression profile and clinical data of osteosarcoma from the TARGET portal, and extracted and normalized via R software. Then, the immune cell infiltration assessed by CIBERSORT and ESTIMATE algorithms. Three survival‐related immune cells and immune score were obtained via Kaplan‐Meier survival analysis, and 232 immune‐related genes were obtained as candidate genes. Enrichment and protein‐protein interaction co‐expression analyses were performed to identify 13 hub genes. Lastly, a seven gene prognostic signature was identified by univariate and multivariate Cox regression analyses. More importantly, our validations and TIMER algorithm suggested this immune‐related prognostic signature a good predictive tool. Our findings have provided novel insights that could demonstrate new targets of immunotherapy in osteosarcoma. John Wiley and Sons Inc. 2020-08-21 2020-10 /pmc/articles/PMC7576232/ /pubmed/32820615 http://dx.doi.org/10.1111/jcmm.15687 Text en © 2020 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Yu, Yiyang
Zhang, Hongliang
Ren, Tingting
Huang, Yi
Liang, Xin
Wang, Wei
Niu, Jianfang
Han, Yu
Guo, Wei
Development of a prognostic gene signature based on an immunogenomic infiltration analysis of osteosarcoma
title Development of a prognostic gene signature based on an immunogenomic infiltration analysis of osteosarcoma
title_full Development of a prognostic gene signature based on an immunogenomic infiltration analysis of osteosarcoma
title_fullStr Development of a prognostic gene signature based on an immunogenomic infiltration analysis of osteosarcoma
title_full_unstemmed Development of a prognostic gene signature based on an immunogenomic infiltration analysis of osteosarcoma
title_short Development of a prognostic gene signature based on an immunogenomic infiltration analysis of osteosarcoma
title_sort development of a prognostic gene signature based on an immunogenomic infiltration analysis of osteosarcoma
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7576232/
https://www.ncbi.nlm.nih.gov/pubmed/32820615
http://dx.doi.org/10.1111/jcmm.15687
work_keys_str_mv AT yuyiyang developmentofaprognosticgenesignaturebasedonanimmunogenomicinfiltrationanalysisofosteosarcoma
AT zhanghongliang developmentofaprognosticgenesignaturebasedonanimmunogenomicinfiltrationanalysisofosteosarcoma
AT rentingting developmentofaprognosticgenesignaturebasedonanimmunogenomicinfiltrationanalysisofosteosarcoma
AT huangyi developmentofaprognosticgenesignaturebasedonanimmunogenomicinfiltrationanalysisofosteosarcoma
AT liangxin developmentofaprognosticgenesignaturebasedonanimmunogenomicinfiltrationanalysisofosteosarcoma
AT wangwei developmentofaprognosticgenesignaturebasedonanimmunogenomicinfiltrationanalysisofosteosarcoma
AT niujianfang developmentofaprognosticgenesignaturebasedonanimmunogenomicinfiltrationanalysisofosteosarcoma
AT hanyu developmentofaprognosticgenesignaturebasedonanimmunogenomicinfiltrationanalysisofosteosarcoma
AT guowei developmentofaprognosticgenesignaturebasedonanimmunogenomicinfiltrationanalysisofosteosarcoma